SUMMIT, N.J.–(BUSINESS WIRE)–Celgene Corporation (NASDAQ: CELG) today announced results from a phase III, randomized, double-blind, international clinical study (AUGMENT). REVLIMID® (lenalidomide) plus rituximab (R2) achieved a highly statistically significant improvement in the primary endpoint of progression-free survival (PFS), compared to rituximab plus placebo, in the final PFS analysis. AUGMENT evaluated the …
Tag Archives: Lymphoma
July, 2018
June, 2018
-
5 June
Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers
CHICAGO–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The results include analyses of the ZUMA-1 study of …
January, 2018
-
18 January
Kite and Pfizer Collaborate to Evaluate Yescarta and Utomilumab in Large B-Cell Lymphoma
FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company (Nasdaq: GILD), announced it has entered into a clinical trial collaboration with Pfizer, Inc. to evaluate the safety and efficacy of the investigational combination of Yescarta™ (axicabtagene ciloleucel) and Pfizer’s utomilumab, a fully humanized 4-1BB agonist monoclonal antibody, in …
-
2 January
FDA Grants Priority Review to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The FDA granted Priority Review for …
December, 2017
-
7 December
Foundation Medicine to Present New Data Supporting FoundationOne®Heme to Advance Personalized Medicine in Blood Cancers
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced that new data generated with FoundationOne®Heme, its comprehensive genomic profiling (CGP) assay for hematologic malignancies and sarcomas, will be presented at the American Society of Hematology (ASH) Annual Meeting. Data from a broad range of blood cancers, including acute myeloid leukemia (AML), myeloproliferative …
October, 2017
-
19 October
FDA Approves Kite’s CAR-T Therapy Yescarta for the Treatment of Large B-Cell Lymphoma
FOSTER CITY, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)–Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or …
-
6 October
Researchers Identify Genetic Drivers of Most Common Form of Lymphoma
DURHAM, N.C. — Lymphoma is the most common blood cancer, but the diagnosis belies a wildly diverse and little understood genetic foundation for the disease that hampers successful treatment. An international research effort led by Duke Cancer Institute scientists has been working to better understand the genetic underpinnings of the …
September, 2017
-
13 September
FDA Accepts for Review Sandoz’s BLA for Proposed Biosimilar Rituximab
Holzkirchen, September 12, 2017 – Sandoz, a Novartis Division, and the pioneer and global leader in biosimilars, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) under the 351 (k) pathway for a proposed biosimilar to the reference medicine, Rituxan®** (rituximab). Rituxan®** is used to …
August, 2017
-
16 August
FDA Grants Priority Review for Seattle Genetics’ Adcetris in Cutaneous T-Cell Lymphoma
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) based on data from the phase 3 ALCANZA trial and two phase 2 investigator-sponsored trials of ADCETRIS (brentuximab vedotin) in patients with cutaneous T-cell …
June, 2017
-
29 June
Seattle Genetics and Takeda Announce Positive Results from Late-Stage NHL Trial
CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Jun. 26, 2017– Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) versus the control arm. ECHELON-1 is …